The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 23, 2017
Filed:
Jun. 27, 2014
The Uab Research Foundation, Birmingham, AL (US);
Us Army Walter Reed Army Medical Center, Chief, Office of Research, Marketing & Policy Dev, Washington, DC (US);
Juntendo University School of Medicine, Division of Nephrology, Department of Internal Medicine, Tokyo, JP;
University of Tennessee Research Foundation, Memphis, TN (US);
Hitoshi Suzuki, Hoover, AL (US);
Run Fan, Omaha, NE (US);
Bruce A. Julian, Birmingham, AL (US);
Jan Novak, Pelham, AL (US);
Zina Moldoveanu, Birmingham, AL (US);
Zhixin Zhang, Omaha, NE (US);
Milan Tomana, Birmingham, AL (US);
Jiri Mestecky, Birmingham, AL (US);
Robert J. Wyatt, Memphis, TN (US);
Yasuhiko Tomino, Tokyo, JP;
Yusuke Suzuki, Tokyo, JP;
Stephen Olson, Rockville, MD (US);
Matthew B. Renfrow, Birmingham, AL (US);
The UAB Research Foundation, Birmingham, AL (US);
US Army Walter Reed Army Medical Center, Chief, Office Of Research, Marketing & Policy Dev Walter Reed Army Institute of Research, Washington, DC (US);
Juntendo University School of Medicine, Division of Nephrology, Department of Internal Medicine, Tokyo, JP;
University of Tennessee Research Foundation, Memphis, TN (US);
Abstract
Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.